Merck’s Keytruda Patents: How Patent Thickets Keep Cancer Drug Prices High
The global pharmaceutical landscape is currently under scrutiny as investigations reveal how companies utilize complex patent strategies to maintain market dominance for high-priced medications. At the centre of this controversy is Keytruda, an immunotherapy drug that has become a focal point for debates regarding patient access and the integrity of the patent system.
The Strategy of Patent Thickets
Drug patents are intended to allow manufacturers to recoup development costs by providing a defined period of exclusivity, typically 20 years in the U.S. However, investigators have identified a pattern where companies create a dense web of patent applications—often referred to as a “patent thicket”—to extend this monopoly well beyond the expiration of initial protections.
In the case of Keytruda, researchers found that Merck & Co. Filed for patents covering changes to formulation, dosing regimens, and combination therapies. By employing “product hops”—the practice of shifting patients to newer versions of the same drug—companies can potentially reset the patent clock. Even when these applications are not granted, the resulting legal and commercial uncertainty can deter competitors from introducing more affordable biosimilars.
Did You Know?
Pembrolizumab, the generic name for Keytruda, was first invented in the early 2000s by Dutch scientists working for a company that was later acquired by Merck, before receiving U.S. Medical approval in 2014.
Pricing Disparities and Legal Hurdles
The financial impact of these patent strategies is compounded by extreme price variations for the drug across the globe. List prices for a single 100-milligram vial range from approximately $850 in Indonesia to $6,015 in the U.S. These disparities are often hidden behind opaque, non-public negotiations between pharmaceutical manufacturers and government health authorities.
In several Latin American nations, the high cost of the drug has led to a surge in the judicialization of healthcare. Thousands of patients have been forced to pursue court orders to secure access to Keytruda after being denied coverage by public health institutions or private insurers. In cases reviewed from Guatemala, Mexico, and Chile, the vast majority of court rulings were decided in favor of the patients.
Expert Insight:
The reliance on judicial intervention to secure life-saving medication suggests a systemic failure in the current healthcare model. When patent monopolies are used to prioritize long-term market dominance over affordability, the burden of access often shifts from the marketplace to the courtroom, creating a precarious environment for patients in need.
Looking Ahead
As the pharmaceutical industry continues to face pressure regarding drug accessibility, the future of the global patent system remains uncertain. Governments may move toward more transparent pricing negotiations to counter the effects of artificial price inflation. As more patent applications related to existing blockbuster drugs continue to move through international patent offices, analysts expect that legal challenges regarding the validity of these “thickets” could increase.
If the trend of judicializing healthcare persists, it may lead to a more fragmented global market where access to critical treatments is dictated by local legal rulings rather than standardized public health policy. The ongoing struggle between maintaining patent-protected innovation and ensuring the affordability of essential medicines remains a defining challenge for global healthcare systems.
Frequently Asked Questions
What is a “product hop” in the pharmaceutical industry?
A product hop occurs when a manufacturer encourages patients to switch from an existing drug to a newer, similar version of that same drug, often to extend the duration of patent exclusivity.
Why do patent applications impact drug prices even if they are not approved?
The act of filing multiple patent applications creates legal and commercial uncertainty, which can deter or delay competitors from entering the market with more affordable biosimilar versions of a drug.
How are patients in Latin America obtaining access to Keytruda?
Many patients are gaining access to the drug through court orders after being denied coverage by public health institutions and private insurers, a phenomenon researchers describe as the judicialization of healthcare.
How should the balance between rewarding pharmaceutical innovation and ensuring equitable patient access to life-saving treatments be defined?